Chimeric peptides targeting the receptor-binding domainof SARS-CoV-2 variants inhibit ACE2 interaction
The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is pivotal in facilitating viral entry and serves as a major target for vaccine development and therapeutics. Despite undergoing mutations aimed at evading host immunity, certain regions within the RBD remain conserved.